



## Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? - caraux et al



**Supplemental Figure S1; Normal Plasma cell count before and after high dose melphalan in MRD<sup>+</sup> patients compared to MRD<sup>-</sup> ones.** Using 7 color-multiparameter flow cytometry, normal plasma cell (N-PC) count were assessed in bone marrow or peripheral blood samples of MRD<sup>+</sup> patients (black circle) compared to MRD<sup>-</sup> ones (open triangle) after induction treatment (1 day before high dose melphalan, HDM), 7 days after HDM and autologous hematopoietic stem cell transplantation (ASCT), 3 months after HDM. N-PC count were also measured in the thawed stem cell leukapheresis product grafted to the patients. Data are the N-PC count for each of the MRD<sup>+</sup> patients (n=12) compared to MRD<sup>-</sup> ones (n=5). The \* indicates that the data in MRD<sup>+</sup> patients compared to MRD<sup>-</sup> ones are significantly different ( $P \leq 0.05$ ). 7 days after HDM+ASCT, the median N-PC count in the bone marrow and in the peripheral blood was higher in MRD<sup>-</sup> patients compared to MRD<sup>+</sup> patients. And, the stem cell products collected from MRD<sup>-</sup> patients and grafted to these patients contained 3 fold higher N-PC counts than those from MRD<sup>+</sup> patients.



**Supplemental Figure S2; Normal Plasma cell count before and after high dose melphalan in MRD<sup>+</sup> patients compared to MRD<sup>-</sup> ones.** Using 7 color-multiparameter flow cytometry, normal plasma cell (N-PC) count were assessed in the bone marrow or peripheral blood samples of MRD<sup>+</sup> (black circle) or MRD<sup>-</sup> (open triangle) patients after induction treatment (1 day before high dose melphalan, HDM), 7 days after HDM and autologous hematopoietic stem cell transplantation (ASCT), 3 months after HDM. N-PC count were also measured in the thawed autologous leukapheresis product grafted to the patients. \* indicates that the data in MRD<sup>+</sup> patients compared to MRD<sup>-</sup> ones are significantly different ( $P \leq .05$ ).